MD Anderson Cancer Center’s Losses Grow

The first two months of the fiscal year saw $102.4 million in operating losses.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, ZARESHKThe financial situation of MD Anderson Cancer Center has continued to decline this fall, with October and November posting $102.4 million in losses, The Cancer Letter reported this week (December 9). In the 2016 fiscal year, operating losses topped $271 million.

According to KPRC 2, layoffs are not out of the question. “We are working collaboratively to reduce expenses and increase revenue to avoid the difficult decision of reducing our dedicated workforce,” MD Anderson told KPRC 2 in a written statement. “While we are taking every measure to avoid reducing positions, we must have contingency plans in place in the event that option becomes necessary.”

Some high-profile initiatives at MD Anderson may face the chopping block, including the Moon Shots Program (different from the one proposed by Vice President Joe Biden), which aims to increase survival rates for numerous cancers. “We are reviewing and reprioritizing our operational investments and looking for expense reductions in all programs, including the Moon Shots Program,” Dan Fontaine, MD Anderson’s executive ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies